Sinocelltech Group Ltd
SSE:688520

Watchlist Manager
Sinocelltech Group Ltd Logo
Sinocelltech Group Ltd
SSE:688520
Watchlist
Price: 36.81 CNY -2.62% Market Closed
Market Cap: 16.4B CNY
Have any thoughts about
Sinocelltech Group Ltd?
Write Note

Sinocelltech Group Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sinocelltech Group Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Sinocelltech Group Ltd
SSE:688520
Revenue
ÂĄ1.9B
CAGR 3-Years
1 688%
CAGR 5-Years
264%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
ÂĄ7.5B
CAGR 3-Years
16%
CAGR 5-Years
84%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ36.4B
CAGR 3-Years
12%
CAGR 5-Years
31%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
ÂĄ2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

Sinocelltech Group Ltd
Glance View

Market Cap
16.4B CNY
Industry
Biotechnology

Sinocelltech Group Ltd. has carved a distinct niche within the biopharmaceutical industry, positioning itself as a leading innovator in the development of biologics. The company, based in China, specializes in the research, production, and commercialization of therapeutic and preventative vaccines, antibodies, and recombinant proteins. By leveraging advanced biotechnology platforms, Sinocelltech navigates the complex landscape of biologic drug development, focusing on high-potential therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Its strategic move to integrate research and production capabilities allows it to maintain tight control over the quality and scalability of its products, providing a competitive edge in the highly regulated and rapidly evolving biotech sector. At the heart of Sinocelltech's business model lies its ability to generate revenue by bringing innovative biologics from the lab to the market—either independently or through strategic partnerships and collaborations. The company capitalizes on its robust pipeline of biologic candidates, some of which have already received market approval and are generating sales both domestically and internationally. Furthermore, Sinocelltech earns revenue from licensing its proprietary technologies and manufacturing capabilities to other pharmaceutical companies, which seek efficient pathways to develop their biologics. This diversified approach not only stabilizes its revenue streams but also reinforces its reputation as a formidable player in the global biopharmaceutical arena.

Intrinsic Value
59.07 CNY
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Sinocelltech Group Ltd's Revenue?
Revenue
1.9B CNY

Based on the financial report for Dec 31, 2023, Sinocelltech Group Ltd's Revenue amounts to 1.9B CNY.

What is Sinocelltech Group Ltd's Revenue growth rate?
Revenue CAGR 5Y
264%

Over the last year, the Revenue growth was 84%. The average annual Revenue growth rates for Sinocelltech Group Ltd have been 1 688% over the past three years , 264% over the past five years .

Back to Top